Novasep S.A.. (3/7/17). "Press Release: Novasep Appoints Xavier de Saint Guilhem as Chief Financial Officer". Lyon.

	Organisation	Novasep S.A.
	Group	Novasep (Group)
	Product	contract manufacturing (drugs)
	Product 2	sample purification / sample separation
	Person	de Saint Guilhem, Xavier (Novasep 201703– CFO before Peugeot Motorcycles + Rhodia + Accenture + Crown Cork & Seal)
	Person 2	Spagnol, Michel (Novasep 201306– CEO before Shasun + Rhodia)

CFO appointment comes as the company gets ready for the next phase of its growth strategy

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces the appointment of Xavier de Saint Guilhem as Chief Financial Officer.

Initially trained at ENSCP, MIT (Massachusetts Institute of Technology) and INSEAD, Xavier joins Novasep following various operational and financial positions held with Rhodia, Accenture, Crown Cork & Seal, Parfums Christian Dior, in Europe or Asia. His latest position was CFO for Peugeot Motocycles.

Dr Michel Spagnol, Chairman and CEO of Novasep, commented: “I am delighted to welcome Xavier in Novasep’s executive team. This appointment comes at a turning point of our Group’s strategy as we successfully refinanced our debt in November 2016 and have invested in key projects to expand our services and fuel future growth. Xavier will play an essential role in the rollout of these projects by bringing his sector expertise and international experience to the management team. I would like to thank Christian Thiry for the work he accomplished as CFO over the past years. All the team joins me in wishing him the very best in his future projects.”

Novasep’s growth potential is rooted on the successful refinancing of the debt the company achieved in November 2016 and in the €100 million invested in its operations and services over the last five years.

Since 2012, several major investments were completed for developing the range of industrial custom manufacturing services: a GMP bioproduction unit of vaccine excipient purified from biomass, a GMP facility for the production of OMEGA-3 purified from fish oil, the expansion of a highly potent active ingredients facility to reach commercial scale production of antibody-drug conjugates (ADC) payloads, and more recently, the dedicated bioconjugation unit to complete the set of services in ADC manufacturing.

These investments have also supported Novasep’s strategy to expand geographically. In the USA, the kilo-lab was expanded to support early stage development of chemical active ingredients. In Asia, the team was extended in China, India and Thailand.

“After this period getting Novasep ‘back to basics’, our future is now clearly to develop further serving our customers by leveraging our robust and innovative industrial manufacturing platform and the expertise of our teams”, added Spagnol, “Whether it will be by organic growth or acquisition, our pool of investors is keen to develop further with us.”

Press Contact:
Sophie Baudouin
Director Communication & Marketing
+33 6 32 08 20 24

About Novasep

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.

Record changed: 2023-06-05